March is National Colorectal Cancer Awareness Month

A new proclamation by President Biden has recognized March 2022 as National Colorectal Cancer Awareness Month.

Colorectal Cancer kills over 50,000 Americans every year, but it is a preventable disease with proper screening. Regular screening should begin at age 45. Due to the COVID pandemic over the last two years, rates of screening for colorectal cancer have plummeted.

Screening for colorectal cancer can save your life. Don’t wait. Get screened now!

Dark Canyon Labs is working on developing a safe and effective taste-free pill prep, with dosing that can be customized for each patient. Our goal is to make the process of prepping for a colonoscopy much better for patients and healthcare professionals alike, to save more lives. Get screened and prevent colorectal cancer!

Dark Canyon Labs Welcomes Dr. Audrey Calderwood to the Advisory Board

Dark Canyon Labs is very pleased to announce the addition of Audrey Calderwood, MD, MS to the Advisory Board. Dr. Calderwood, a gastroenterologist and Associate Professor of Medicine at Dartmouth, is a well known leader in the field of colonoscopy preparation, and is funded by the NIH to study colonoscopy preparation. She was instrumental in the development and validation of the Boston Bowel Preparation Scale, which is now the accepted standard for assessing the cleanliness of the colon at the time of the colonoscopy procedure.

We welcome her expertise to the Advisory Board as we move forward with DCL-101, our taste-free colonoscopy pill prep and its associated AI technology.

Read more about Dr. Calderwood here.

March is Colorectal Cancer Awareness Month

Colorectal Cancer kills over 50,000 Americans every year, but it is a preventable disease with proper screening. Regular screening should begin at age 45. Due to the COVID pandemic over the last year, rates of screening for colorectal cancer have plummeted.

Screening for colorectal cancer can save your life. Don’t wait. Get screened now!

Dark Canyon Labs is working on developing a safe and effective taste-free pill prep, with dosing that can be customized for each patient. Our goal is to make the process of prepping for a colonoscopy much better for patients and healthcare professionals alike, to save more lives. Get screened and prevent colorectal cancer!

For additional information about screening and colorectal cancer:

• Colorectal Cancer Alliance

• American Cancer Society

• American Gastroenterological Association

• American College of Gastroenterology

Dark Canyon Labs Announces Positive Phase 2 Trial Results for Taste-Free Colonoscopy Prep, DCL-101, in Peer-Reviewed Publication

Dark Canyon Labs is excited to announce publication of positive Phase 2 results in Clinical and Translational Gastroenterology. View the entire article here.

Study Highlights

What is known:

• The gold standard for colonoscopy prep safety and efficacy is 4L polyethylene glycol-electrolyte solution (PEG-ELS).

• 40% of patients have known risk factors for a suboptimal prep, and 4L PEG-ELS is recommended for this population.

• The tolerability of 4L PEG-ELS is limited by its taste and volume.

What is new here:

• DCL-101 is a novel pill-based colonoscopy prep that is taste-free and compositionally identical to 4L PEG-ELS. Safety and efficacy of DCL-101 appear to be similar to 4L PEG-ELS.

• DCL-101 is significantly better tolerated than 4L PEG-ELS. 87% of patients found DCL-101 to have “no taste” or “good taste.” The vast majority of patients found DCL-101 “easy to take,” and experienced far less dread during the prep.

• Palatability has a large impact on overall colon prep tolerability.

Dark Canyon Labs Strengthens U.S. Patent for Novel Taste-Free Pill Prep, DCL-101

Dark Canyon Laboratories, LLC is pleased to report that we have received “Notice of Allowance” from the United States Patent and Trademark Office for a Continuation of our Divisional Colon Lavage System patent for the Novel DCL-101 Taste-Free Pill Prep.

This addition further strengthens the intellectual property portfolio defining our novel colonoscopy preparation technology.

The newly expanded U.S. patent joins a comprehensive list of patents already issued to Dark Canyon Labs in Japan, Australia, Canada, China, Hong Kong and the EU for a novel Colon Lavage System.

Isn't it time for a better colonoscopy prep?

Dark Canyon Labs Granted Hong Kong Patent for DCL-101 Taste-Free Pill Prep

Dark Canyon Labs was granted Hong Kong Patent No. 1167572 for development of a novel Colon Lavage System on May 22, 2020.

Dark Canyon Labs is especially pleased to announce that this Hong Kong Patent for DCL-101, a novel taste-free pill prep, used for colonoscopy preparation, joins patents for DCL-101 already issued in the US, Japan, Australia, Canada, China and the EU.

EU Patent Granted to Dark Canyon Labs

Dark Canyon Labs was notified of intention to grant European Union Patent No. EP2421373 for development of a novel Colon Lavage System on April 15, 2019.

Dark Canyon Labs is especially pleased to announce that this EU Patent for DCL-101, a novel taste-free pill prep, used for colonoscopy preparation, joins patents for DCL-101 already issued in the US, Japan, Australia, Canada, and China. Patent is pending in Hong Kong.

March is Colorectal Cancer Awareness Month

Colorectal cancer is the third leading cause of cancer-related deaths in men and women in the United States, and kills over 50,000 people annually. Colorectal cancer can be prevented by getting screened.

Historically, one of the obstacles of getting a screening colonoscopy has been the bad taste and tolerability of the colonoscopy prep, which must be taken prior to the procedure. Dark Canyon Labs has developed a new colonoscopy prep, DCL-101, which is a taste-free pill prep. A Phase 2 clinical trial was successfully completed, with Phase 3 to begin in the near future.

Dark Canyon Labs is determined to make a safe and effective taste-free pill prep available for patients. Our goal is to make the process of prepping for a colonoscopy much easier and to increase colonoscopy screening rates, thereby saving lives. Get screened and prevent colorectal cancer!

For more information, visit the American Society for Gastrointestinal Endoscopy.

Phase 2 Results of Dark Canyon Labs' Novel Pill Prep DCL-101 Selected as one of the "Most Innovative and Impactful Abstracts at ACG 2018"

The American College of Gastroenterology’s (ACG) Innovation & Technology Committee recently selected 22 abstracts as the “Most Innovative and Impactful Abstracts at ACG 2018”, from over 2600 abstracts that were presented at the ACG’s annual Scientific Meeting in Philadelphia, PA in October 2018.

Dark Canyon Labs’ presentation of Phase 2 study results of the Novel Pill Prep, DCL-101, was selected as one of the “Most Innovative and Impactful Abstracts at ACG 2018.”

The ACG Innovation & Technology Committee is a forum that allows members to gather information about new ideas, innovations and technologies in gastroenterology. Selecting the “Most Innovative and Impactful Abstracts at ACG 2018” allowed the Committee to highlight the clinical significance and importance of emerging technologies in gastroenterology.

See the complete ACG report here.

Dark Canyon Labs to present at ACG 2018

Dale Bachwich, MD from Dark Canyon Labs will be presenting Phase 2 Data for the novel colonoscopy pill prep DCL-101 at the annual scientific meeting of the American College of Gastroenterology (ACG) in Philadelphia, PA on October 9, 2018.

For additional information, contact darkcanyonlabs@me.com

Dark Canyon Labs announces completion of Phase 2 Clinical Trial

Dark Canyon Labs is pleased to announce the completion of a multicenter, randomized, investigator blinded, non-inferiority Phase 2 Clinical Trial.  DCL-101, a novel Pill Prep, was compared to standard split-dose GoLYTELY® in adult outpatients undergoing routine colonoscopy.

Based on tolerability, safety, and efficacy results, Dark Canyon Labs is excited to announce that DCL-101 will move ahead for further evaluation in two definitive Phase 3 trials.  

Watch for additional details soon. For more information, contact darkcanyonlabs@me.com  

Dark Canyon Labs announces start of Phase 2 Clinical Trial in December 2016

Dark Canyon Labs is pleased to announce that subject enrollment begins in December for a Phase 2 trial comparing the safety and efficacy of DCL-101 vs. GoLYTELY® in preparing the bowel for routine colonoscopy.  DCL-101 is Dark Canyon Labs' novel capsule prep that eliminates the need to drink the salty-tasting solution of other preps, completely transforming the patient experience. GoLYTELY® is the current gold standard bowel prep in terms of efficacy, so will be used as the comparator.  

The trial is now listed on ClinicalTrials.gov, a service of the National Institutes of Health.

To learn more about enrolling in the clinical trial, please contact Philip Calvillo from Robarts Clinical Trials, at 626-658-0870 or  Philip.Calvillo@robartsinc.com 

Dark Canyon Laboratories to present at 2016 AGA Tech Summit

Dr. Bachwich will be presenting details about Dark Canyon Labs' new colonoscopy prep, DCL-101,  at the "Shark Tank" Session of the 2016 AGA Tech Summit in Boston, MA on Thursday, March 31, 2016. This conference on GI Innovation and Technology identifies unmet needs in gastroenterology and highlights promising new technologies.  A distinguished panel of moderators will provide valuable feedback.  

Dark Canyon Labs supports Colorectal Cancer Awareness Month in March

Colon cancer kills 50,000 patients every year and is the third leading cause of cancer in men and women in the U.S.  Many of these deaths can be prevented with regular screening.  Dark Canyon Laboratories is committed to providing patients with a much better experience during the colonoscopy prep process.  A better tolerated prep could help save lives by increasing the colon cancer screening rate. If patients don't dread the process, they will be more likely to comply with the current screening recommendations.

Learn more about colorectal cancer from the American College of Gastroenterology and from the American Cancer Society.